Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations

UCL Medical School, Royal Free Campus, London, UK.
HIV Medicine (Impact Factor: 3.99). 02/2010; 11(7):432-8. DOI: 10.1111/j.1468-1293.2009.00809.x
Source: PubMed


Effective antiretroviral therapy (ART) has transformed the care of people with HIV, but it is important to monitor time trends in indicators of treatment success and antic future changes.
We assessed time trends from 2000 to 2007 in several indicators of treatment success in the UK Collaborative HIV Cohort (CHIC) Study, and using national HIV data from the Health Protection Agency (HPA) we developed a model to project future trends.
The proportion of patients on ART with a viral load <50 HIV-1 RNA copies/mL increased from 62% in 2000 to 84% in 2007, and the proportion of all patients with a CD4 count <200 cells/microL decreased from 21% to 10%. During this period, the number of patients who experienced extensive triple class failure (ETCF) rose from 147 (0.9%) to 1771 (3.9%). The number who experienced such ETCF and had a current viral load >50 copies/mL rose fromz 118 (0.7%) to 857 (1.9%). Projections to 2012 suggest sustained high levels of success, with a continued increase in the number of patients who have failed multiple drugs but a relatively stable number of such patients experiencing viral loads >50 copies/mL. Numbers of deaths are projected to remain low.
There have been continued improvements in key indicators of success in patients with HIV from 2000 to 2007. Although the number of patients who have ETCF is projected to rise in the future, the number of such patients with viral loads >50 copies/mL is not projected to increase up to 2012. New drugs may be needed in future to sustain these positive trends.

Download full-text


Available from: Tim Chadborn, Oct 01, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents a detailed complexity-quality analysis of various MPEG-2 to MPEG-4 transcoding architectures that perform spatial resolution reduction. The optimization of several processing components is also presented.
    No preview · Conference Paper · Feb 2002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To estimate life expectancy for people with HIV undergoing treatment compared with life expectancy in the general population and to assess the impact on life expectancy of late treatment, defined as CD4 count <200 cells/mm(3) at start of antiretroviral therapy. Cohort study. Outpatient HIV clinics throughout the United Kingdom. Population Adult patients from the UK Collaborative HIV Cohort (UK CHIC) Study with CD4 count ≤ 350 cells/mm(3) at start of antiretroviral therapy in 1996-2008. Life expectancy at the exact age of 20 (the average additional years that will be lived by a person after age 20), according to the cross sectional age specific mortality rates during the study period. 1248 of 17,661 eligible patients died during 91,203 person years' follow-up. Life expectancy (standard error) at exact age 20 increased from 30.0 (1.2) to 45.8 (1.7) years from 1996-9 to 2006-8. Life expectancy was 39.5 (0.45) for male patients and 50.2 (0.45) years for female patients compared with 57.8 and 61.6 years for men and women in the general population (1996-2006). Starting antiretroviral therapy later than guidelines suggest resulted in up to 15 years' loss of life: at age 20, life expectancy was 37.9 (1.3), 41.0 (2.2), and 53.4 (1.2) years in those starting antiretroviral therapy with CD4 count <100, 100-199, and 200-350 cells/mm(3), respectively. Life expectancy in people treated for HIV infection has increased by over 15 years during 1996-2008, but is still about 13 years less than that of the UK population. The higher life expectancy in women is magnified in those with HIV. Earlier diagnosis and subsequent timely treatment with antiretroviral therapy might increase life expectancy.
    Full-text · Article · Jan 2011 · BMJ (online)
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is concern that antiretroviral therapy (ART) use with only clinical monitoring for failure will result in high rates of transmission of virus with resistance to drugs currently in use. A stochastic simulation model of transmission of HIV, natural history and the effect of ART, was developed and used to predict the proportion of new infections with resistance according to whether and when viral load monitoring is introduced. In our base model, there was predicted to be 12.4% of new HIV infections with primary antiretroviral resistance in 2020 if clinical monitoring is used throughout, compared with 5.4 and 6.1% if viral load-guided switching (based on viral load measured every 6 months, with switch determined by a value >500 copies/ml) was introduced in 2010 or 2015, respectively. The death rate for those on ART was lowest when viral load monitoring was used, but the overall death rate in all infected people was higher if viral load monitoring was introduced at the expense of scale-up in HIV diagnosis and ART initiation beyond their 2010 coverage levels (4.7 compared with 3.1 per 100 person-years). To preserve current first-line drugs for the long term there is an eventual need for some form of cheap and practical viral load monitoring in resource-limited settings. However, a delay in introduction of 5 years has limited consequences for resistance transmission so the current priority for countries' ART programmes is to increase HIV testing and provide treatment for all those in need of ART.
    No preview · Article · Feb 2011 · AIDS (London, England)
Show more